In a previous publication, we demonstrated that patients with NSCLC exhibit higher percentages of circulating leukocyte-PLT complexes compared to HD and, particularly, complexes of CD4+ T cell-PLTs and CD14+ cell-PLTs can be used as a predictive biomarker of the development and severity of immune-related adverse events associated to ICI therapy [22]. Here, CD14 is linked to non-small cell lung carcinoma.